A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancerKimberly Blackwell, M. S. Berger, P. Kelly Marcom et al.|Journal of Clinical Oncology|2004Cited by 90
Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancerK. Blackwell, M. S. Berger, Harold J. Burstein et al.|Journal of Clinical Oncology|2005Cited by 66
A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancerKim T. Blackwell, M. S. Berger, M. J. Sorensen et al.|Journal of Clinical Oncology|2004Cited by 44